These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 100040)

  • 1. Liposomes in therapeutic and preventive medicine: the development of the drug-carrier concept.
    Gregoriadis G
    Ann N Y Acad Sci; 1978; 308():343-70. PubMed ID: 100040
    [No Abstract]   [Full Text] [Related]  

  • 2. Use of liposomes for the enhancement of the cytotoxic effects of cytosine arabinoside.
    Mayhew E; Papahadjopoulos D; Rustum YM; Dave C
    Ann N Y Acad Sci; 1978; 308():371-86. PubMed ID: 279297
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of Gaucher's disease with liposome-entrapped glucocerebroside: beta-glucosidase.
    Belchetz PE; Crawley JC; Braidman IP; Gregoriadis G
    Lancet; 1977 Jul; 2(8029):116-7. PubMed ID: 69198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Gaucher's disease: results of enzymatic treatment with beta glucosidase acid].
    Genovés Terol I; Martínez Porcal C; Ferrrer Lorente B; Menor Serrano F; Dalmau Serra J
    An Esp Pediatr; 1997 Apr; 46(4):406-8. PubMed ID: 9214240
    [No Abstract]   [Full Text] [Related]  

  • 5. Experiences after long-term treatment of a type I Gaucher disease patient with liposome-entrapped glucocerebroside: beta-glucosidase.
    Gregoriadis G; Neerunjun D; Meade TW; Goolamali SK; Weereratne H; Bull G
    Birth Defects Orig Artic Ser; 1980; 16(1):383-92. PubMed ID: 6778529
    [No Abstract]   [Full Text] [Related]  

  • 6. Enhancement of chemotherapeutic effect by entrapping 1-beta-D-arabinofuranosylcytosine in lipid vesicles and its mode of action.
    Kataoka T; Kobayashi T
    Ann N Y Acad Sci; 1978; 308():387-94. PubMed ID: 279298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repacement therapy in Gaucher disease.
    Beutler E; Dale GL; Kuhl W
    Birth Defects Orig Artic Ser; 1980; 16(1):369-81. PubMed ID: 6778528
    [No Abstract]   [Full Text] [Related]  

  • 8. Multivesicular liposomes containing cytarabine for slow-release Sc administration.
    Kim S; Howell SB
    Cancer Treat Rep; 1987 May; 71(5):447-50. PubMed ID: 3567968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement by tetrahydrouridine of 1-beta-D-arabinofuranosylcytosine (cytarabine) oral activity in L1210 leukemic mice.
    Neil GL; Moxley TE; Manak RC
    Cancer Res; 1970 Aug; 30(8):2166-72. PubMed ID: 4990003
    [No Abstract]   [Full Text] [Related]  

  • 10. Role of liposome type and route of administration in the antitumor activity of liposome-entrapped 1-beta-D-arabinofuranosylcytosine against mouse L1210 leukemia.
    Rustum YM; Dave C; Mayhew E; Papahadjopoulos D
    Cancer Res; 1979 Apr; 39(4):1390-5. PubMed ID: 421223
    [No Abstract]   [Full Text] [Related]  

  • 11. Combination chemotherapy in sequence for the treatment of L1210 leukemia.
    Roberts D; Hilliard SL
    Cancer Res; 1978 Aug; 38(8):2317-20. PubMed ID: 667827
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical pharmacology of 1-beta-d-arabinofuranosyl cytosine.
    Ho DH; Frei E
    Clin Pharmacol Ther; 1971; 12(6):944-54. PubMed ID: 5289712
    [No Abstract]   [Full Text] [Related]  

  • 13. Recent advances in sustained release of antineoplastic drugs using liposomes which avoid uptake into the reticuloendothelial system.
    Allen TM; Mehra T
    Proc West Pharmacol Soc; 1989; 32():111-4. PubMed ID: 2780575
    [No Abstract]   [Full Text] [Related]  

  • 14. Liposomes in Gaucher type I disease: use in enzyme therapy and the creation of an animal model.
    Gregoriadis G; Weereratne H; Blair H; Bull GM
    Prog Clin Biol Res; 1982; 95():681-701. PubMed ID: 6812092
    [No Abstract]   [Full Text] [Related]  

  • 15. Circadian optimization of the treatment of L1210 leukemia with 1-beta-D-arabinofuranosylcytosine, cyclophosphamide, vincristine and methylprednisolone.
    Burns ER; Scheving LE
    Chronobiologia; 1980; 7(1):41-51. PubMed ID: 7438892
    [No Abstract]   [Full Text] [Related]  

  • 16. New directions in the treatment of Gaucher disease.
    Futerman AH; Sussman JL; Horowitz M; Silman I; Zimran A
    Trends Pharmacol Sci; 2004 Mar; 25(3):147-51. PubMed ID: 15019270
    [No Abstract]   [Full Text] [Related]  

  • 17. Role of cholesterol in enhancing the antitumor activity of cytosine arabinoside entrapped in liposomes.
    Mayhew E; Rustum YM; Szoka F; Papahadjopoulos D
    Cancer Treat Rep; 1979; 63(11-12):1923-8. PubMed ID: 526925
    [No Abstract]   [Full Text] [Related]  

  • 18. Development of optimal drug administration strategies for cancer - chemotherapy in the framework of systems theory.
    Acharya RS; Sundareshan MK
    Biomed Sci Instrum; 1983; 19():71-6. PubMed ID: 6683572
    [No Abstract]   [Full Text] [Related]  

  • 19. On methods for testing and achieving cancer chronotherapy.
    Halberg F; Nelson W; Cornelissen G; Haus E; Scheving LE; Good RA
    Cancer Treat Rep; 1979 Aug; 63(8):1428-30. PubMed ID: 476717
    [No Abstract]   [Full Text] [Related]  

  • 20. Chemotherapy of leukemia L1210 in mice with 1-beta-d-arabinofuranosylcytosine hydrochloride. I. Influence of treatment schedules.
    Kline I; Venditti JM; Tyrer DD; Goldin A
    Cancer Res; 1966 May; 26(5):853-9. PubMed ID: 5936445
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.